T1	intervention 0 11	Anastrozole
T2	control 19 28	tamoxifen
T3	eligibility 627 683	postmenopausal women with hormone-receptor-positive DCIS
T4	duration 1005 1012	5 years
T5	outcome-Measure 1290 1304	all recurrence
T6	duration 1694 1732	Between March 3, 2003, and Feb 8, 2012
T7	No-of-participants 1746 1750	2980
T8	intervention-participants 1856 1860	1449
T9	control-participants 1885 1889	1489
T10	outcome 1955 1980	breast cancer recurrences
T11	outcome 2048 2066	overall recurrence
T12	intervention-value 2068 2070	67
T13	control-value 2102 2104	77
T14	outcome 2287 2293	deaths
T15	intervention-value 2309 2311	33
T16	control-value 2331 2333	36
T17	outcome 2487 2500	adverse event
T18	intervention-value 2534 2538	1323
T19	intervention-value 2546 2549	91%
T20	control-value 2566 2570	1379
T21	control-value 2578 2581	93%
T22	adverse-effect 2646 2655	fractures
T23	adverse-effect 2657 2679	musculoskeletal events
T24	adverse-effect 2681 2702	hypercholesterolaemia
T25	adverse-effect 2708 2715	strokes
T26	adverse-effect 2742 2754	muscle spasm
T27	adverse-effect 2756 2791	gynaecological cancers and symptoms
T28	adverse-effect 2793 2811	vasomotor symptoms
T29	adverse-effect 2817 2837	deep vein thromboses
